Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword

Publication date: Jun 26, 2023

CME credits: 1. 00 Valid until: 27-06-2024 Claim your CME credit at https://reachmd. com/programs/cme/treatment-oab-and-managed-care-professional-balancing-double-edged-sword/15674/ Tune in to this live broadcast on overactive bladder! Experts David Staskin, MD, and Roger Dmochowski, MD, discuss evidence-based best practices in the management and treatment of OAB and integrate challenging case studies throughout the broadcast. =

Concepts Keywords
Diabetes Anti
Karen Beta
Magician Bladder
Pharmacology Care


Type Source Name
disease MESH white matter disease
disease MESH cognitive dysfunction
disease MESH dementias
disease MESH stroke
disease MESH multiple sclerosis
disease MESH chronic conditions
disease MESH social problem
drug DRUGBANK Tropicamide
disease MESH cystitis
disease MESH interstitial cystitis
disease MESH syndrome
disease MESH urinary tract infection
disease MESH urinary incontinence
disease MESH nocturia
drug DRUGBANK Nonoxynol-9
disease MESH overactive bladder
drug DRUGBANK Coenzyme M
disease MESH drug interactions
disease MESH comorbidity
drug DRUGBANK Dihydrotachysterol
disease MESH glycosuria
drug DRUGBANK Norepinephrine
disease MESH urinary retention
drug DRUGBANK Isoxaflutole
disease MESH urge incontinence
disease MESH obstructive sleep apnea
disease MESH glaucoma
disease MESH hypertension
disease MESH tachycardia
drug DRUGBANK Troleandomycin
disease MESH neurogenic bladder
disease MESH dry eyes
drug DRUGBANK Antimony
disease MESH causes
disease MESH overtreatment
drug DRUGBANK Aspartame

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *